ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "Bisphosphonates"

  • Abstract Number: 1875 • 2019 ACR/ARP Annual Meeting

    Subject Characteristics and Changes in Bone Mineral Density After Transitioning from Denosumab to Alendronate in the Denosumab Adherence Preference Satisfaction (DAPS) Study

    David Kendler1, Arkadi Chines 2, Patricia Clark 3, Peter R. Ebeling 4, Michael McClung 5, Yumie Rhee 6, Shuang Huang 2, Robert Kees Stad 7 and Nick Freemantle 8, 1University of British Columbia, Vancouver, BC, Canada, 2Amgen Inc., Thousand Oaks, CA, 3Hospital Infantil de Mexico Federico Gómez and National University of Mexico, Mexico City, Mexico, 4Monash University, Melbourne, Victoria, Australia, 5Oregon Osteoporosis Center, Portland, OR, 6Yonsei University College of Medicine, Seoul, Republic of Korea, 7Amgen Inc., Rotkreuz, Zug, Switzerland, 8University College London, London, England, United Kingdom

    Background/Purpose: There are limited data on patients transitioning from denosumab (DMAb) to bisphosphonates (BPs). The Denosumab Adherence Preference Satisfaction (DAPS) study (NCT00518531) reported that alendronate…
  • Abstract Number: 2657 • 2019 ACR/ARP Annual Meeting

    The Association Between Bisphosphonates and Giant Cell Arteritis: A Retrospective Cohort Study

    Salman Mahmood1, Yuanyuan Ji 2, Yi Peng 2 and Zaki Abou Zahr 1, 1Hennepin Healthcare, Minneapolis, MN, 2Chronic Disease Research Group, Hennepin Healthcare Research Institute, Minneapolis, MN

    Background/Purpose: Bisphosphonates have been used to treat disorders of bone metabolism for several years. A common adverse reaction associated with their use constitutes a transient…
  • Abstract Number: 293 • 2018 ACR/ARHP Annual Meeting

    Temporal Trends and Factors Associated with Bisphosphonate Drug Holidays

    Jeffrey R. Curtis1, Rui Chen1, Tarun Arora1, Shanette Daigle1, Robert Matthews1, Huifeng Yun1, Nicole Wright2, Ayesha Jaleel3, Elizabeth Delzell4 and Kenneth Saag5, 1University of Alabama at Birmingham, Birmingham, AL, 2Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 3University of Alabama at Birmingham, Birmngham, AL, 4Retired - University of Alabama at Birmingham, Birmingham, AL, 5UAB, Birmingham, AL

    Background/Purpose: Safety concerns related to osteoporosis (OP) medication use and temporary or permanent cessation of bisphosphonate therapy (e.g. ‘drug holidays’) have generated appreciable attention in…
  • Abstract Number: 1256 • 2018 ACR/ARHP Annual Meeting

    A Customized Health Information Technology Effectively Identifies and Directs Bone Health Services in Rural Veterans with Osteoporosis Risk Factors

    Shardool Patel1, Zachary L. Anderson1, Grant W. Cannon2, Brian C. Sauer2 and Karla L. Miller2, 1Salt Lake City VA Medical Center, Salt Lake City, UT, 2Salt Lake City VA Medical Center and University of Utah, Salt Lake City, UT

    Background/Purpose: Osteoporosis is underdiagnosed and undertreated in the Veterans Health Administration (VHA), especially in rural Veterans. Tools to identify risk factors in Veterans are available.…
  • Abstract Number: 1818 • 2018 ACR/ARHP Annual Meeting

    Greater BMD Gains with Denosumab Vs Risedronate in Glucocorticoid-Treated Subjects: Results from the Final 24-Month Analysis of a Randomized, Double-Blind, Double-Dummy Study

    Kenneth Saag1, Nicola Pannacciulli2, Piet Geusens3, Jonathan D. Adachi4, Osvaldo D. Messina5, Jorge Morales-Torres6, Ronald Emkey7, Peter W. Butler2, Xiang Yin2 and Willem F. Lems8, 1University of Alabama at Birmingham, Birmingham, AL, 2Amgen Inc., Thousand Oaks, CA, 3Maastricht University, Maastricht, Netherlands, 4McMaster University, Hamilton, ON, Canada, 5Cosme Argerich Hospital, Buenos Aries, Argentina, 6Hospital Aranda de la Parra, Leon, Mexico, 7Emkey Arthritis & Osteoporosis Clinic, Wyomissing, PA, 8VU University Medical Centre, Amsterdam, Netherlands

    Background/Purpose: Denosumab 60 mg subcutaneously every 6 months (Q6M) increased spine and hip BMD significantly more than risedronate 5 mg orally once daily (QD) at…
  • Abstract Number: 2299 • 2018 ACR/ARHP Annual Meeting

    Subgroup Analysis of the Effect of Denosumab Compared with Risedronate on Percentage Change in Lumbar Spine Bone Mineral Density at 24 Months in Glucocorticoid-Treated Individuals

    Kenneth Saag1, Nicola Pannacciulli2, Piet Geusens3, Jonathan D. Adachi4, Eric Lespessailles5, Jorge Malouf6, Bente Langdahl7, Peter W. Butler2, Xiang Yin2 and Willem F. Lems8, 1University of Alabama, Birmingham, AL, 2Amgen Inc., Thousand Oaks, CA, 3Maastricht University, Maastricht, Netherlands, 4McMaster University, Hamilton, ON, Canada, 5University Hospital Orleans, Orleans, France, 6Hospital San Pablo, Barcelona, Spain, 7Aarhus University, Aarhus, Denmark, 8VU University Medical Centre, Amsterdam, Netherlands

    Background/Purpose: We previously demonstrated that denosumab increased lumbar spine and total hip bone mineral density (BMD) significantly more than risedronate at 12 and 24 months…
  • Abstract Number: 2808 • 2018 ACR/ARHP Annual Meeting

    T-Score As an Indicator of Fracture Risk on Therapy: Evidence from Romosozumab Vs Alendronate Treatment in the Active-Controlled Fracture Study in Postmenopausal Women with Osteoporosis at High Risk Trial

    Felicia Cosman1, E. Michael Lewiecki2, Peter R Ebeling3, Eric Hesse4, Nicola Napoli5, Daria B Crittenden6, Maria Rojeski6, Wenjing Yang6, Cesar Libanati7 and Serge Ferrari8, 1Columbia University, New York, NY, 2New Mexico Clinical Research & Osteoporosis Center, Albuquerque, NM, 3Monash University, Melbourne, Australia, 4University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 5Campus Bio-Medico University of Rome, Rome, Italy, 6Amgen Inc., Thousand Oaks, CA, 7UCB Pharma, Brussels, Belgium, 8Geneva University Hospital, Geneva, Switzerland

    Background/Purpose: BMD is a strong predictor of fracture risk in untreated patients. Recent evidence suggests that BMD achieved during treatment also reflects fracture risk; thus,…
  • Abstract Number: 2812 • 2018 ACR/ARHP Annual Meeting

    Evaluation of Cortical Microarchitecture, Bone Stiffness and Bone Remodeling in Patients with Atypical Femoral Fracture

    Mariana O Perez1, Diogo S Domiciano1, Luciene M Reis2, Vanda Jorgetti2 and Rosa M R Pereira1, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, 2Nephrology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures and subtrochanteric/diaphyseal localization that have been related to long-term bisphosphonate therapy. Patients with AFF exhibit…
  • Abstract Number: 333 • 2017 ACR/ARHP Annual Meeting

    Atypical Femoral Fracture in Patients of a Rheumatology Service: Clinical, Radiographic and Bone Histomorphometric Data

    Mariana O Perez1, Diogo S Domiciano1, Vanda Jorgetti2 and Rosa M R Pereira1, 1Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil, 2Nephrology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, Brazil

    Background/Purpose: Atypical femoral fractures (AFF) are low energy femoral fractures with a specific radiographic pattern and subtrochanteric / diaphyseal localization that have been related to…
  • Abstract Number: 828 • 2017 ACR/ARHP Annual Meeting

    The Impact of the Duration of Bisphosphonate Drug Holidays on Hip Fracture Rates

    Jeffrey R. Curtis1, Rui Chen2, Zixu (Eric) Li2, Tarun Arora2, Kenneth Saag3, Nicole C. Wright4, Shanette Daigle2, Meredith Kilgore5 and Elizabeth Delzell6, 1Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Department of Medicine, Veterans Administration San Diego Healthcare System/UC San Diego, San Diego, CA, 4Epidemiology, University of Alabama at Birmingham, Birmingham, AL, 5Health Care Organization & Policy, University of Alabama at Birmingham, Birmingham, AL, 6Retired - University of Alabama at Birmingham, Birmingham, AL

    Background/Purpose: Given FDA warnings, drug holidays (temporary or permanent discontinuation) of bisphosphonates (BPs) after long-term (3-5 years) continuous therapy is becoming increasingly common in the…
  • Abstract Number: 839 • 2017 ACR/ARHP Annual Meeting

    Use of Bisphosphonate and Risk of Incident Atrial Fibrillation in a Population-Based Study

    Shanshan Sheehy1, Christine Peloquin2 and Tuhina Neogi3, 1Clinical Epidemiology Research & Training Unit, Boston University, Boston, MA, 2Boston University School of Medicine, Boston, MA, 3Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA

    Background/Purpose: Bisphosphonates remain the first-line agent prescribed medication for the prevention and treatment of osteoporosis. Apart from concern about atypical fractures, another concern about risk…
  • Abstract Number: 1194 • 2017 ACR/ARHP Annual Meeting

    Are Bisphosphonates Efficacious in Knee Osteoarthritis? A Meta-Analysis of Randomized Controlled Trials

    Mikala C. Osani1, Elizaveta Vaysbrot1, Raveendhara R. Bannuru2, Mia-Cara Musetti1 and Timothy E. McAlindon1, 1Division of Rheumatology, Tufts Medical Center, Boston, MA, 2Center of Integrative Medicine and Division of Rheumatology, Tufts Medical Center, Boston, MA, Boston, MA

    Background/Purpose: One of the key aspects of osteoarthritis (OA) pathogenesis is subchondral bone remodeling.  Bisphosphonates have been touted as disease-modifying agents for OA due to…
  • Abstract Number: 1212 • 2017 ACR/ARHP Annual Meeting

    Relation of Incident Bisphosphonate Use to Bone Marrow Lesion Volume in Knee Osteoarthritis

    Tuhina Neogi1, Jeffrey Duryea2, Na Lu1, Jingbo Niu1 and Yuqing Zhang1, 1Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA, 2Radiology, Brigham & Women's Hospital/ Harvard Medical School, Boston, MA

    Background/Purpose: Bone marrow lesions (BMLs) are important contributors to pain and progression of knee OA. There has been recent interest in bisphosphonates as a potential…
  • Abstract Number: 1228 • 2017 ACR/ARHP Annual Meeting

    Postmenopausal Breast Cancer Patients on Aromatase Inhibitor Therapy and Their Increased Risk of Fragility Fracture

    Anna Lafian1, Julia Suh2 and Karina Torralba3, 1Internal Medicine, Arrowhead Regional Medical Center, Colton, CA, 2Internal Medicine, Loma Linda University, Loma Linda, CA, 3Internal Medicine/Rheumatology, Loma Linda University, Loma Linda, CA

    Background/Purpose: Postmenopausal women with breast cancer have higher osteoporosis risk due to declining estrogen levels and use of aromatase inhibitors (AIs). The American Society of…
  • Abstract Number: 1850 • 2017 ACR/ARHP Annual Meeting

    Efficacy of Zoledronic Acid and Denosumab in the Treatment of Patients with Low Back Pain and Modic Changes: A Proof of Principle Trial

    Guoqi Cai1, Laura Laslett1, Dawn Aitken2, Andrew Halliday3, Feng Pan2, Petr Otahal1, Deb Speden4, Tania Winzenberg1 and Graeme Jones2, 1Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, 2Musculoskeletal Unit, Menzies Institute for Medical Research, University of Tasmania, Hobart, Australia, 3Radiology, Royal Hobart Hospital, Hobart, Australia, 4Royal Hobart Hospital, Hobart, Australia

    Background/Purpose: Low back pain (LBP) is a common and debilitating problem. There are currently very limited pharmacological treatments for LBP. Vertebral endplate subchondral bone abnormalities…
  • 1
  • 2
  • 3
  • 4
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.